BHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of Migraine (P7-12.009)
{{output}}
Objective: Describe the rationale and design of a pivotal Phase 2 clinical trial of BHV-2100 for acute treatment of migraine. Background: Trans... ...
